By John Eastman - August 10, 2012 | Tickers: BAYRY.PK, TSRX | 0 Comments

John is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

There is something to be said for slow, steady, and cerebral; especially, if you are invested in a biopharmaceutical firm. This industry does not turn out products overnight. It is a slow, long and grueling process of development, clinical trial testing, FDA maneuvering, safe (GMP) good manufacturing practice production, effective distributing and marketing, and obtaining key partners. And then there is the money! Costs of clinical trial testing are exorbitant and continue to rise.

A steady hand at the controls is a must. That includes long term commitment, persistence, and an ability to adjust to new and changing events, conditions, and regulations in theU.S. and worldwide alike. It also requires smart decision-making and skills from both sides of the brain. My observation is that the management at Trius Therapeutics (NASDAQ: TSRX) has just that.

The company released its financial results for the second quarter ended June 30, 2012. While there are increases in losses from recent comparative periods, they are attributable to common business operations and environment in this industry when at the clinical trial stage. Here is an update on the firms results and their steady progress on development:

Cash

The company reported cash, cash equivalents and investments totaling $83.8 million June 30, 2012. This is sufficient to support their operations.

Operations

For the second quarter of 2012, Trius reported a net loss of $14.4 million. This compares to a 2011 net loss of $10.0 million. For the six months ended June 30, 2012, the company reported a net loss of $22.0 million compared to $20.1 million for the same period in 2011. Note: The increase in net loss during the three and six months ended June 30, 2012 was largely due to increased clinical trial expenses as compared to the same period in 2011.

Share P/L

Visit link:
Trius Therapeutics Holds Steady and Reports Positive Financials